![]() |
The Difference in Guanfacine Formulations for ADHD...
December 1, 2014 - Clinical , Featured By: Katharine Cimmino, Editor-in-Chief – Attention-deficit/hyperactivity disorder (ADHD) is the most common pediatric psychiatric disorder, and it affects the education, social interactions, and over-all wellbeing of both children and adolescents.1 Symptoms of ADHD can persist into adulthood, and those with this disorder are more likely to suffer from other mental health co-morbidities.2 According to guidelines… |
![]() |
Recombinant Factor IX (Alprolix) Brings Hope for Hemoph...
December 1, 2014 - Featured , In the News / Politics By: Benedette Cuffari, BS Toxicology Candidate c/o 2015 – Hemophilia B is an inherited bleeding disorder that is caused by a substantially reduced or complete lack of blood clotting factor IX. Therefore, people suffering from hemophilia B experience bleeding episodes that cause pain, irreversible joint damage, and life threatening hemorrhages. Approximately 28,000 people are currently… |
![]() |
Off-Label Antidepressant Use in Pediatric Patients with...
November 1, 2014 - Clinical , Featured By: Jacqueline Meaney, PharmD Candidate c/o 2015, University at Buffalo: School of Pharmacy and Pharmaceutical Sciences — Psychotropic medications are typically used in conjunction with cognitive behavioral therapy to treat behavioral problems that affect children with autism spectrum disorder (ASD). Symptoms of ASD typically include a need for routines (change intolerance), difficulty with verbal and… |
![]() |
Accountable Care Organizations...
November 1, 2014 - Featured , In the News / Politics By: Stephanie Chiu and Elissa Tam, PharmD Candidates c/o 2015 — According to the Dartmouth Atlas project, health care spending in the United States has risen dramatically and yet health outcomes are not improving; meanwhile, many other countries that spend far less per person than the United States have better health outcomes.1 Studies have since… |
![]() |
FDA-Approved Afrezza: An Inhaled Alternative to Injecta...
October 1, 2014 - Featured , In the News / Politics By: Elissa Tam, PharmD Candidate c/o 2015 – Patients with Type 1 or Type 2 diabetes who cannot control their glucose levels simply by taking oral medications have to inject insulin daily. They also have to measure their glucose levels by using strips and lancets on a regular basis. For patients, especially elderly ones, the… |
![]() |
HIV Pre-Exposure Prophylaxis...
September 1, 2014 - Clinical , Featured By: Elissa Tam PharmD Candidate c/o 2015 – HIV/AIDS continues to be a persistent problem in the United States and in various countries around the world. In 2010 alone, there were around 47,500 new HIV infections in the United States with about 1.1 million Americans living with HIV at the end of 2010.1 When left… |
![]() |
Reservoir of Migraine Therapies Includes Analgesics, AE...
September 1, 2014 - Clinical , Featured By Davidta Brown, Senior Staff Editor – The pain, nausea, and light or sound sensitivity that comprise a migraine attack afflict more than 10% of individuals around the world, easily making migraines one of the most globally debilitating diseases of the present day.1 According to the International Headache Society (IHS), migraines are defined by both… |
![]() |
Drug Shortages: Effects & Costs in the United Stat...
August 1, 2014 - Featured , Professional Advice / Opinions By: Valentina DiGangi,PharmD Candidate c/o 2017, Brandon Hu, PharmD Candidate c/o 2018, Sang Hyo Kim, Staff Editor, Samantha Lau, PharmD Candidate c/o 2018, and Seowoo Yoon, PharmD Candidate c/o 2018 – What does a clinician do when there is limited access to a particular drug, such as morphine? Should they treat a patient who is… |
![]() |
Migraine Relief at the Push of a Button...
August 1, 2014 - Featured , In the News / Politics By: Davidta Brown, Senior Staff Editor – A new therapeutic device has seemingly leapt from the pages of a science fiction novel and into the hands of migraine sufferers around the world. Worn over the forehead and sending electromagnetic stimulation directly into the supraorbital trigeminal nerves, the cranial nerve stimulator offered by Belgian biotechnology company… |
![]() |
Tailored Tablets...
August 1, 2014 - Featured , In the News / Politics By: Azia Tariq, Staff Editor – Truly personalized medication is the goal of researchers in the pharmaceutical and biotechnological industries. For example, when a patient requires a precise dose that is not manufactured as a tablet, the tablet will be broken up in order to deliver the dose as close as possible. Not only is… |
![]() |
The Importance of the Measles Vaccine: Should We Be Vac...
July 1, 2014 - Featured , In the News / Politics By: Sherin Pathickal, PharmD Candidate c/o 2016 – The mandatory receipt of vaccinations as a preventive public health measure has long been a controversial issue in our society.1 Despite the popular use of immunizations, many reservations about vaccine constituents and their safety have prevailed, leading to increasing numbers of unvaccinated people.1 Opponents of vaccinations have… |
![]() |
I Have a Problem...
June 1, 2014 - Featured , Professional Advice / Opinions By: Sang Hyub Kim, DPM Candidate c/o 2018, New York College of Podiatric Medicine – I was diagnosed with ulcerative colitis in 2009. For the past five years, I have literally taken tons of immunosuppressant medications, ranging from corticosteroids (prednisone), to chemotherapeutics (6-Mercaptopurine) in an effort to suppress the inflammation in my colon. Currently, I… |
![]() |
Asking Questions...
May 1, 2014 - Professional Advice / Opinions By: Bharat Kirthivasan, Co-Copy Editor (Content-focused) – It’s graduation season and some students are moving from academics to professional life. Others are taking a step in that direction. I myself am wrapping up my Ph.D. and working full time in the pharmaceutical industry as a formulation scientist. During my Ph.D., I’ve served as a Teaching… |
![]() |
FDA Approves Drug Elosulfase Alfa (Vimizim™) for Muco...
May 1, 2014 - Featured , In the News / Politics By: Erica Dimitropoulos Co-Copy Editor [Content- Focused] – On February 14, 2014, elosulfase alfa (Vimizim™) became an FDA-approved enzyme replacement therapy for Morquio A Syndrome, a type of mucopolysaccharidosis (MPS IVA).1 Elosulfase alfa was granted priority review and was also the first drug to receive the Rare Pediatric Disease Priority Review Voucher that motivates the development… |
![]() |
Possible New Prostate Cancer Screening...
May 1, 2014 - Featured , In the News / Politics By: Fatema Elias, Senior Staff Editor – Prostate cancer occurs when abnormal cells form in the tissues of the prostate gland. It often develops in men over the age of 50, and the numbers of estimated new cases and of deaths from prostate cancer in the United States in 2013 are 238,590 and 29,720, respectively.1… |
![]() |
The Use of Topical Opioid Treatment for Pressure Ulcer ...
May 1, 2014 - Clinical , Featured By: Katharine Cimmino, Editor-in-Chief – Pressure ulcers can be a painful condition decreasing the quality of life of patients and prolonging hospital stays.1 About 10% of hospital inpatients and 26% of hospice admissions have pressure sores.2 Pressure ulcers are injuries that occur when pressure is applied for prolonged periods of time over bony prominences.1 There… |
![]() |
Riociguat (Adempas®) New Drug for Pulmonary Hypertens...
April 1, 2014 - Clinical , Featured By: Hayeon Na, Co-Copy Editor [Content-Focused] – On October 8th of 2013, Bayer’s new drug riociguat (Adempas®) was approved for the treatment of patients whose pulmonary hypertension (PH) belongs in WHO groups 1 and 4.1 Riociguat (Adempas®) is a soluble guanylate cyclase (sGC) stimulator, and currently the only one of its kind on the market.… |
![]() |
Tasimelteon (Hetlioz®): First FDA Approved Pharmacolo...
April 1, 2014 - Featured , In the News / Politics By: Beatrisa Popovitz, Senior Staff Editor – On January 31st 2014, the FDA announced the release of a revolutionary new drug, tasimelteon (Hetlioz®). Tasimeleton is the first developed treatment of non-24-hour sleep-wake cycle syndrome in blind individuals.1 Formulated by Vanda Pharmaceuticals Inc., this melatonin receptor agonist works by binding to and activating the MT1 and… |
![]() |
Dietary Supplements and Their Potential Dangers...
March 1, 2014 - Professional Advice / Opinions By: Fatema Elias, Staff Writer – With the New Year and everyone committing to their New Year resolutions, more and more patients are coming into the pharmacy asking for recommendations, particularly for weight loss dietary supplements. I hesitate to recommend an over-the-counter dietary supplement for weight loss. However, we as pharmacists and pharmacy students have… |
![]() |
The Importance of Organ Donation: Perspectives and the ...
March 1, 2014 - Featured , Professional Advice / Opinions By: James Schurr, PharmD Candidate c/o 2014 and Jennifer Miao, PharmD Candidate c/o 2014 With very special thanks to Jessica Melore and Jennifer McDermott, PharmD, BCPS of NewYork-Presbyterian Hospital – Jessica Melore was 16 years old, a senior in high school, and co-captain of the tennis team when her life took a drastic turn. While… |
![]() |
Psychiatric Prescriptions in the Fight Against Juvenile...
March 1, 2014 - Clinical , Featured By: Davidta Brown, Senior Staff Editor – In August 2013, the results of a yearlong safety study were published in the Journal of American Medical Association (JAMA) Psychiatry.1 The study, which followed the health status of about 43,000 youths aged 6 to 24, confirmed and built upon a previously noted trend in adults: that the… |
![]() |
Long Term PPI Use Heightens Concern of Associated Healt...
February 1, 2014 - Clinical , Featured By: Tamara Yunusova, Senior Staff Editor – Proton Pump Inhibitors (PPIs) are acid-reducing agents that have multiple uses in the treatment and prophylaxis of conditions such as peptic ulcer diseases, H. Pylori infection, Zollinger-Ellison syndrome, GERD, and NSAID gastroduodenal ulcers. Their versatility in treating a wide range of conditions, unparalleled efficacy over their Histamine-2-receptor antagonist… |
![]() |
Low Literacy and Medication Management?...
February 1, 2014 - Professional Advice / Opinions By: Jenny Park, Pharm. D. Candidate c/o 2015 – As the Affordable Care Act brings health care to many people who are currently uninsured, healthcare providers should expect an increase in the number of patients who don’t understand their plan, disease states, and medications. Health literacy is defined as “the degree to which individuals have… |
![]() |
The Increasing Roles of Pharmacists in Transplant Outco...
February 1, 2014 - Featured , In the News / Politics By: Jenny Park, PharmD Candidate c/o 2015 – Medication adherence is a big part of a patient’s success in managing their health conditions. The Annals of Internal Medicine estimated that the cost of medication non-adherence may reach up to $289 billion each year.1 It is crucial for organ transplant patients to take powerful immunosuppressants to… |
![]() |
Pharmacy Across the Border: An Interview with Sherif Gu...
February 1, 2014 - Featured , Professional Advice / Opinions By: Sang Hyo Kim, Staff Editor – For the brand new year, we present an interview with Sherif Guorgui, the current Vice-President of Pharmacy at the Ontario Pharmacists Association and the former 2011-2012 President of the Ontario College of Pharmacists in Canada. Mr. Guorgui graduated in 1998 from the Faculty of Pharmacy at the University… |
![]() |
New Hepatitis C Drug Receives FDA Approval...
January 1, 2014 - Clinical , Featured By: Ada Seldin, Staff Editor – On November 22, 2013, simeprevir (Olysio®), a new agent to treat chronic hepatitis C, received approval under the FDA’s priority review program. Simeprevir is an NS3/4A protease inhibitor that blocks the replication of the hepatitis C virus. Two other drugs from the same class, boceprevir and telaprevir, which were… |
![]() |
Direct Association of HIV and Early Kidney Damage in Wo...
January 1, 2014 - Featured , In the News / Politics By: Elizabeth Kopec, PharmD Candidate c/o 2014, South University School of Pharmacy at Columbia, SC – Human immunodeficiency virus (HIV) is a global pandemic, with approximately 35.3 million people infected in 2012. The United States currently has 1.3 million people living with HIV, with 20,000 deaths occurring every year due to acquired immune deficiency syndrome… |
![]() |
Newly Approved: Macitentan (Opsumit®)...
December 1, 2013 - Clinical , Featured By: Rebecca Gilene, PharmD Candidate c/o 2014, St. Louis College of Pharmacy – The FDA approved macitentan (Opsumit®) on October 18, 2013 for the treatment of pulmonary arterial hypertension.1 Pulmonary arterial hypertension, often referred to as PAH, is a disease characterized by high blood pressure in the arteries between the heart and lungs. An increase… |
![]() |
Ponatinib Taken Off the Market...
December 1, 2013 - In the News / Politics By: Sherine Jaison, PharmD Candidate c/o 2015 – The leukemia chemotherapy drug ponatinib (Iclusig) has just been taken off the market. The drug was under investigation by the Food and Drug Administration (FDA) following several reports of serious and life threatening blood clots and narrowing of the blood vessels.1 Ponatinib is a BCR-ABL tyrosine kinase… |
![]() |
Hospital Drug Shortages...
December 1, 2013 - Featured , In the News / Politics By: Hamid Razaki, PharmD – Drug shortages seen across pharmacies in the United States continue to be an issue in patient care. A drug product shortage is defined as a supply issue that affects how the pharmacy prepares or dispenses a drug product, or that influences patient care when prescribers must use an alternative agent.1… |
![]() |
Still a Long Road Ahead for New Hepatitis C Treatment...
December 1, 2013 - In the News / Politics By: Ramya Mathew, PharmD Candidate c/o 2015 – Vertex Pharmaceuticals, an American biotechnology company based in Cambridge, Massachusetts, has been researching a new “nuke” for the treatment of Hepatitis C called VX-135. This nucleotide polymerase inhibitor is currently undergoing clinical trials, but the FDA has put the research on a partial hold due to findings… |
![]() |
Zecuity(TM): Novel Treatment Option for Migraines...
November 1, 2013 - Clinical By: Arya Mathew, PharmD Candidate c/o 2014 – About twelve percent of the U.S. population suffers from migraines, affecting adult women three times more than adult men. Migraines are returning attacks of moderate to severe, throbbing or pulsing pain, usually on one side of the head. Along with the severe pain, migraine sufferers also experience… |
![]() |
Does Moxifloxacin Increase the Risk of Dysglycemia?...
November 1, 2013 - Clinical , Featured By: Nathan Trustman, PharmD Candidate c/o 2014, AMSCOP at LIU – The antibiotic class known as the fluoroquinolones is widely used in both outpatient and inpatient settings. They provide bactericidal effects by inhibiting DNA gyrase and topoisomerase IV enzymes in bacteria. The systemic agents that are most commonly used in clinical practice include ciprofloxacin, levofloxacin,… |
![]() |
New Treatment for a Deficiency in Iron-Supplement Thera...
October 1, 2013 - Clinical By: Davidta Brown, Staff Editor – For the estimated 7.5 million individuals in the United States living with iron deficiency anemia (IDA), there is now a new alternative to iron supplements or time-consuming, repetitive infusions. On July 25, 2013, the FDA approved ferric carboxymaltose injection (Injectafer®) for the treatment of IDA, especially in patients who… |
![]() |
Canagliflozin (Invokana®): New Type 2 Diabetes Drug...
October 1, 2013 - Clinical By: Sang Hyo Kim, Staff Editor – On March 29th 2013, the U.S Food and Drug Administration approved canagliflozin (Invokana®), a new form of a diabetic drug for patients with type 2 diabetes mellitus.1 Canagliflozin is in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors and is the only oral, once-daily… |
![]() |
Meet the Dean: Interview with Dean DiGate...
October 1, 2013 - Featured , Professional Advice / Opinions By: Katharine Cimmino, Editor-in-Chief and Erica Dimitropoulos, Senior Staff Editor – Just last month, St. John’s University College of Pharmacy and Health Sciences kindly welcomed a new Dean into our family, Dean Russell J. DiGate. Dean DiGate is a highly experienced educator and academic leader. He attended the University of Rochester, where… |
![]() |
Olmesartan Medoxomil Label Revision...
September 1, 2013 - In the News / Politics By: David Ong, PharmD Candidate c/o 2014 – Manipulating the renin-angiotensin system is one of the many ways drugs are used to treat hypertension. By blocking key steps in the renin-angiotensin cascade, blood pressure decrease may be achieved. Angiotensin II receptor blockers (ARBs) represent one of the drug classes that utilize the aforementioned mechanism. ARBs… |
![]() |
Drugs and Diseases: The Survival Manual...
August 1, 2013 - Professional Advice / Opinions By: Beatrisa Popovitz, Staff Editor – You may have heard the countless horror stories passed on by upperclassman of how D&Ds seep into the crevices of our brains and take over our psyches to inevitably make us breathe, sleep, and speak pharmacy. Stressing out over exams and investing what may seem like all of your… |
![]() |
Solving the HCV Enigma: Current and Future Drug Therapy...
July 1, 2013 - Clinical , Featured By: Tamara Yunusova, Senior Staff Editor – Approximately 3.2 million Americans have chronic hepatitis C infection.1 While acute cases are not common, rates of chronic hepatitis C continue to surge due to the recent discovery of the virus in 1989 and consequently, the establishment of a test screening for HCV antibodies in 1992.1 HCV has… |
![]() |
Can a Pharmacist Prevent the Next Pileup?...
May 1, 2013 - Clinical By: Moisey Rafailov, PharmD Candidate c/o 2015 – It was early in the morning on New York’s Route 684 when a car hit a tractor-trailer and continued driving without regard. Imagine that, when later stopped by a police officer, the driver said that the accident was her pharmacist’s fault. What if I were to tell… |
![]() |
Purple Glove Syndrome...
May 1, 2013 - Clinical , Featured By: Sharon Janak, PharmD Candidate c/o 2013 – How can we distinguish between vascular injury and Purple Glove Syndrome (an adverse effect of phenytoin)? What are the warning signs and symptoms? Phenytoin is an anticonvulsant used to treat generalized tonic-clonic and partial seizures. It stabilizes neuronal cell membranes of the motor cortex by facilitating the… |
![]() |
Pilltalk: Innovation to Simplify Patient Counseling...
May 1, 2013 - Featured , In the News / Politics By: Mitesh Patel, PharmD Candidate 2014 – $1.2 trillion- This is what the United States spends on healthcare. At 17% of GDP, this sector accounts for more spending in the U.S. than education, defense, welfare, and pension.1 By 2016, our expenditure on healthcare will rise to $1.6 trillion.1 As our health care spending increases, Americans… |
![]() |
AUVI-Q™: The Newest Epinephrine Device to Hit the Mar...
May 1, 2013 - In the News / Politics By: Diana Gritsenko, Pharm D. Candidate c/o 2015 – Most of us who work in a community pharmacy setting will usually get a few scripts a month for an Epi-pen™. An Epi-pen™ is a device that autoinjects epinephrine (also known as adrenaline) into a patient who is experiencing anaphylaxis. Anaphylaxis is a severe, whole-body allergic… |
![]() |
Plan B® Pill Now Available Without Prescription to Wom...
May 1, 2013 - Featured , In the News / Politics By: Bansri Patel – As of May 1st 2013, Plan B®, the brand name emergency contraception pill will now be available to women aged fifteen and older. It will also be sold in the drug store aisles, as opposed to its current location behind the pharmacy counter. When levonorgestrel (Plan B®) first entered the market,… |
![]() |
The Honors Program Spotlight...
April 1, 2013 - Events By: Steve Soman – The St. John’s University Honors Program features small classes, faculty mentoring, and an impressive number of academic and cultural opportunities for students to excel. These opportunities range from performances at the Metropolitan Opera, New York City Ballet, and the New York Philharmonic to museum visits and Manhattan walking tours. For students… |
![]() |
FDA Approves New Drug ‘Tofacitinib’ for Rheumatoid ...
April 1, 2013 - Clinical , Featured By: Erica Dimitropoulos, Senior Staff Editor – Rheumatoid arthritis is a painful and often debilitating autoimmune disease characterized by symmetric polyarthritis, most commonly of the proximal interphalangeal and metacarpophalangeal joints, elbows, knees, ankles, and spine.1 Its clinical manifestations vary, from a slowly progressing onset of fatigue and musculoskeletal discomfort to a sudden and worsening destruction… |
![]() |
Pharmaceutical Industry: More than One Way In...
April 1, 2013 - Events By: David Ong, Pharm.D. Candidate c/o 2014 – There are many research opportunities available for pharmacists after graduation. However, most pharmacy students do not know enough about these opportunities as they progress through pharmacy school. Jason Lee, a guest speaker at the monthly Drug Information Association meeting, explained the different aspects of industry and industry… |
![]() |
New FDA Approval: Fycompa® to Treat Seizures...
March 1, 2013 - Clinical , Featured By: Bhavini Shah, PharmD Candidate c/o 2013 – Fycompa® (perampanel) has received the U.S. Food and Drug Administration (FDA) approval for the adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older.1 The drug, manufactured by Eisai Inc., is already approved for use in Iceland,… |
![]() |
FDA Approves New Indication for Botox (Onabotulinumtoxi...
March 1, 2013 - Clinical , Featured By: Bethsy Jacob, PharmD Candidate 2014 – On January 18, 2013, the U.S. Food and Drug Administration (FDA) announced a new approval for Botox, generically known as OnabotulinumtoxinA. Patients diagnosed with urinary incontinence due to an overactive bladder can be prescribed Botox, if they are unable to take or are unresponsive to anticholinergic medications. This… |
![]() |
A Look at Primary Medication NonAdherence and How it ca...
February 1, 2013 - Featured , In the News / Politics By: Erica Dimitropoulos, Assistant Student Editor – Although clinical trials can affirm the efficacy and advantages of all marketed medications, it is obvious that patients cannot benefit from a drug that they choose not to take. Therefore, promoting medication adherence is one of the easiest and most affordable ways to improve treatment outcomes. In order… |